All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Bristol Myers Squibb, Sarah Cannon Research Institute expand cancer clinical trial partnership using Accelero platform
Research collaboration, oncology, clinical trials platform, community-based network - Read more

Global Brain, TOHO HOLDINGS launch TOHO Ventures corporate venture capital fund for drug discovery biotechnology
Venture capital, drug discovery, AI/ML, biotechnology - Read more

Sandoz, EirGenix license pertuzumab biosimilar for breast cancer, milestone-based deal with upfront payment
Licensing deal, oncology, antibody, milestone payments - Read more

Laekna, Qilu Pharma license AKT inhibitor LAE002 for China, up to RMB 2.04M ($287K) deal
Licensing deal, small molecule, oncology, milestone payments - Read more

ABL Bio, Eli Lilly partner on blood-brain barrier platform, $40M upfront, $2.562B milestones
Research collaboration, neurological, milestone payments, royalties - Read more

Chiesi Group, Aliada Therapeutics license blood-brain barrier platform for lysosomal storage disorders with upfront payment
Licensing deal, rare disease, neurological, enzyme replacement therapy, milestone payments - Read more

Octant, Bristol Myers Squibb collaborate on neurodegenerative disease small molecules, $15M upfront plus milestones
Research collaboration, neurological, small molecule, AI/ML, milestone payments - Read more

Evotec receives $5M milestone from Bristol Myers Squibb after FDA clears CELMoD IND application
Molecular glue degrader, oncology, strategic, milestone payment - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Alkermes reports Ph2 success for alixorexton targeting orexin 2 receptor in narcolepsy type 2, advances to Ph3
Small molecule, neurological, orexin 2 receptor agonist, narcolepsy, excessive daytime sleepiness - Read more

Altimmune's pemvidutide dual GLP-1/glucagon agonist achieves positive Ph2b results for metabolic dysfunction-associated steatohepatitis treatment
Protein therapy, metabolic, dual GLP-1 glucagon agonist, MASH, liver fibrosis - Read more

Novartis plans approval filing for GanLum malaria drug following Ph3 success in parasitic infection treatment
Small molecule, infectious disease, antimalarial, malaria, drug resistance - Read more

CureGene presents preclinical data for CG-0416 thyroid hormone receptor beta agonist targeting obesity at conference
Small molecule, metabolic, thyroid hormone receptor beta agonist, obesity, muscle preservation - Read more

Artiva plans pivotal rheumatoid arthritis trial for AlloNK targeting B-cells following positive Ph2 autoimmune results
Cell therapy, autoimmune, NK cell therapy, rheumatoid arthritis, B-cell depletion, off-the-shelf - Read more

Neurogene reports positive Ph1/2 interim data for NGN-401 gene therapy in pediatric Rett syndrome patients
Gene therapy, neurological, adeno-associated virus, Rett syndrome, pediatric population, MECP2 gene - Read more

Immatics reports Ph1 proof-of-concept for IMA402 (PRAME) and IMA401 bispecific antibodies targeting solid tumors
Bispecific antibody, cancer, TCR bispecific, solid tumors, PRAME target - Read more

THE GOOD
Company Launches

Syrna Therapeutics emerges from stealth with covalent translation inhibitors targeting disease-causing mRNA proteins
Small molecule, strategic, RNA-targeted therapeutics, covalent inhibitors - Read more

THE GOOD
Fundraises

Indivi raises CHF15M ($18.7M), precision medicine biomarkers for Alzheimer's drug development
Biomarker discovery, Alzheimer disease, neurological, precision medicine, clinical-stage - Read more

Centessa Pharmaceuticals raises $250M public offering, clinical-stage pharmaceutical company
Clinical-stage, pharmaceutical, platform technology - Read more

NanoViricides raises $6M registered direct offering for working capital and operations
Infectious disease, antiviral, preclinical - Read more

Beacon Biosignals raises $86M Series B, portable EEG brain data platform
Neurological, EEG platform, biomarker discovery, AI/ML platform - Read more [Paywall]

Biohaven raises $150M equity offering, replacing funds after FDA rejection
Neurological, small molecule, clinical-stage, rare disease - Read more

Kala Bio raises $375K convertible loan, eye disease drug developer lifeline
Ophthalmology, rare disease, clinical-stage, small molecule - Read more

THE GOOD
Regulatory

FDA introduces "plausible mechanism" pathway to accelerate approval of bespoke therapies for rare diseases
Gene therapy, rare disease, strategic, operational - Read more

THE GOOD
Strategic Plans

Novo Nordisk slashes Wegovy weight-loss drug prices up to 33% in India amid competition
GLP-1 agonist, metabolic disease, competitive, cost reduction - Read more

Leap Therapeutics rebrands as Cypherpunk Technologies, pivots to crypto after winding down cancer program
Monoclonal antibody, oncology, strategic, major transaction - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Business Development & Partnerships

AbbVie, Calico end 11-year aging disease collaboration after $1.75B investment, 100 layoffs planned
Research collaboration, neurological, small molecule, aging - Read more

THE BAD
Earnings & Finances

Bayer pharma sales miss expectations amid Xarelto generic competition, CEO touts newer drug launches
Small molecule, cardiovascular, financial, competitive - Read more

Bayer faces Eylea biosimilar competition, cuts early cancer programs amid continued Xarelto genericization pressures
Monoclonal antibody, ophthalmology, financial, competitive, revenue impact - Read more

THE BAD
Layoffs

nChroma Bio lays off staff, refocuses on hepatitis drug ahead of clinical trials
Gene therapy, infectious disease, operational, cost reduction - Read more

Metagenomi cuts 25% workforce, CEO departs to focus on hemophilia A program MGX-001
Gene therapy, rare disease, operational, cost reduction - Read more

THE BAD
Strategic Plans

Bayer discontinues Vividion STAT3 inhibitor and three other early-stage cancer programs
Small molecule, oncology, strategic, cost reduction - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here